# An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer

> **NCT04492293** · PHASE2 · UNKNOWN · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 115 (estimated)

## Conditions studied

- Bladder Urothelial Cancer

## Interventions

- **DRUG:** ICP-192

## Key facts

- **NCT ID:** NCT04492293
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-27
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-06-30
- **Target enrollment:** 115 (ESTIMATED)
- **Last updated:** 2024-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04492293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04492293, "An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04492293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*